Thanks for joining the march!

Thanks for signing our petition

In just 11 days we attracted 2115 signatures!

Latest newsletter

Read our latest update: the April 2019 newsletter

Latest News

Innovation Fuels Survival Gains in Multiple Myeloma

In the past 20 years, we’ve been very fortunate in the development of effective myeloma therapies and have seen remarkable...
Continue Reading

Daratumumab cuts risk for progression in multiple myeloma

For patients with newly diagnosed multiple myeloma, the addition of daratumumab to lenalidomide and dexamethasone is associated with a reduced...
Continue Reading

Multiple Myeloma Research Review

Highlights include: • Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. • MGUS risk in relatives of patients with multiple...
Continue Reading

Guyon Espiner investigates Pharmac: The NZ Buyer’s Club

Guyon Espiner reveals how lung cancer patients are buying cut-price drugs from India, as other New Zealanders fundraise, petition and...
Continue Reading

Early Treatment for Smoldering Multiple Myeloma

Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder and is described as an intermediate stage between monoclonal gammopathy of...
Continue Reading

Lenalidomide Offers Patients With Smoldering Myeloma Option to Prevent Progression

Lenalidomide (Revlimid) significantly reduced the risk for smoldering multiple myeloma to progress to cancer among patients with moderate to high risk, according...
Continue Reading


Every quarter we’ll post news and information in our myeloma newsletter. If you would like to join the community of patients and caregivers receiving this subscribe below.